Keyword: AstraZeneca

AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi.

AstraZeneca is partnering with Cancer Research UK to debut a new research facility that will focus on using CRISPR and other functional genomics tech.

Having failed to improve outcomes in metastatic NSCLC, the anti-CTLA4 antibody has now missed the mark in a phase 3 head and neck cancer trial.

AstraZeneca moved the Dynavax-partnered TLR9 agonist into the trial in the belief it could improve time to loss of asthma control.

Combining EGFR inhibitors with drugs targeting Aurora kinase A killed cancer cells permanently, a University of California, San Francisco, team found.

The readout suggests that, if anything, adding tremelimumab to PD-L1 drug Imfinzi results in worse outcomes in metastatic NSCLC.

AstraZeneca is dropping one of its midstage cancer drugs—mTOR inhibitor vistusertib—despite encouraging early clinical data.

South Korea’s Yuhan has licensed its lung cancer drug lazertinib to Janssen Biotech for $50 million upfront and another $1.2 billion in milestones.

AstraZeneca will collaborate with U.K. startup-supporter Medicines Discovery Catapult to develop the use of sound waves in mass spectrometry.

The multipart deal will see AstraZeneca hand over the upfront cost and commit to billions in milestones to swell its immuno-oncology pipeline.